Eli Lilly and Company

05/31/2026 | Press release | Distributed by Public on 05/31/2026 06:19

Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive[...]

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.
Eli Lilly and Company published this content on May 31, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on May 31, 2026 at 12:19 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]